E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
New York Heart Association (NYHA) class II/III heart failure and LVEF <50% |
|
E.1.1.1 | Medical condition in easily understood language |
Diseases associated with heart failure |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10010684 |
E.1.2 | Term | Congestive heart failure |
E.1.2 | System Organ Class | 100000004849 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the safety and tolerability of single doses of REGN5381 in patients with heart failure and reduced left ventricular ejection fraction (LVEF) with evidence of congestion. |
|
E.2.2 | Secondary objectives of the trial |
• Evaluate the effects of single doses of REGN5381 on hemodynamic parameters • Evaluate the effects of REGN5381 on a clinical biomarker of heart failure severity • Characterize the pharmacokinetics (PK) of single doses of REGN5381 • Assess the immunogenicity of REGN5381 |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Pharmacogenomic sub-study |
|
E.3 | Principal inclusion criteria |
1. Male or female patients between 18 to 75 years of age (inclusive) at the screening visit 2. Body mass index (BMI) between 18 and 35 kg/m2, inclusive, rounded to the nearest whole number 3. Ambulatory patients with New York Heart Association (NYHA) class II/III heart failure and symptoms of congestion (eg, dyspnea on exertion) 4. Left ventricular ejection fraction (LVEF) <50% on echocardiogram within 6 months prior to randomization 5. NT-proBNP >300 pg/mL or Brain Natriuretic Peptide (active form) (BNP) >125 pg/mL as described in the protocol within 30 days prior to randomization measured by the local laboratory 6. Pulmonary capillary wedge pressure (PCWP) ≥15 mmHg on right heart catheterization (RHC) the morning of anticipated study drug dose administration 7. Systolic blood pressure (SBP) ≥100 mmHg at the screening visit and on day -1 8. Hematocrit >30% at the screening visit and day -1
Other protocol-defined Inclusion Criteria apply |
|
E.4 | Principal exclusion criteria |
1. Currently taking IV vasodilators and/or inotropes 2. Taking (valsartan/sacubitril), a phosphodiesterase (PDE) inhibitor (eg, sildenafil), or a soluble guanylate cyclase stimulator (SGCS; ie, vericiguat) within 2 weeks of the screening visit or planning on taking valsartan/sacubitril, a PDE inhibitor, or a SGCS at any point during the study 3. More than moderate valvular regurgitation/stenosis on echocardiogram within 6 months prior to randomization 4. Known infiltrative or hypertrophic cardiomyopathy 5. Acute coronary syndrome within prior 6 months of randomization 6. History of cardiac arrest 7. Cardiac surgery within 3 months of randomization 8. Pacemaker or defibrillator placement within prior 30 days of randomization 9. Severe chronic obstructive pulmonary disease (COPD) (defined as Forced Expiratory Volume in 1st second [FEV1] <50% of predicted or Global Initiative for Chronic Obstructive Lung Disease [GOLD] 3 or 4) 10. Pulmonary arterial hypertension (WHO Group 1) 11. Congenital heart disease (repaired or unrepaired) 12. Inability to lie flat for cardiac catheterization
Other protocol-defined Exclusion Criteria apply |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Incidence and severity of treatment-emergent adverse events (TEAEs) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Through the end-of-study (EOS) visit |
|
E.5.2 | Secondary end point(s) |
1: Change from baseline in pulmonary capillary wedge pressure (PCWP) 2: Change from baseline right atrial pressure (RAP) 3: Change from baseline cardiac output (CO) 4: Change from baseline systemic vascular resistance (SVR) 5: Change from baseline mean pulmonary artery pressure (mPAP) 6: Change from baseline pulmonary vascular resistance (PVR) 7: Change from baseline in systolic blood pressure (SBP) 8: Change from baseline in diastolic blood pressure (DBP) 9: Change from baseline in mean arterial pressure (MAP) 10: Change from baseline in pulse rate (PR) 11: Change from baseline in N-terminal pro-brain natriuretic peptide (NT-proBNP) 12: Concentrations of REGN5381 in serum 13: Immunogenicity, as measured by anti-drug antibodies (ADA) to REGN5381 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1-6: Over 6 hours post-dose administration 7-10: Over the first 6 hours, 24 hours post-dose administration (day 1), through the EOS 11: To 6 hours, 24 hours post-dose administration (day 1), through the EOS 12-13: Through the EOS visit |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 9 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Poland |
Belgium |
Hungary |
Moldova, Republic of |
Turkey |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |